The re-ding bioCD3/CD20 dual resistance has been approved for 5 clinical projects and is expected to raise US$1 billion for a secondary listing in Hong Kong.

Recently, CDE's latest publicity shows that Regeneron's CD3/CD20 dual-specific antibody REVEN1979 injection has been approved for the treatment of B-cell non-Hodgkin's lymphoma (B-NHL) patients who have relapsed or are difficult to treat after past systemic treatment.
regenerative cells, regenerative regeneration, is produced through its unique Veloci-Bi dual-specific antibody platform.
REGN1979 kills cancer cells by binding to B-cell tumor proteins (CD20) and immune system T-cell lipolys (CD3), and the product in the study has been awarded orphan drug qualification by the FDA for the treatment of diffuse large B-cell lymphoma (DLBCL) and figular lymphoma (FL).
Based on data released by Regeneratives at the 61st Annual Meeting of the American Society of Hematology (ASH) in 2019, REGN1979 showed good results in the treatment of a variety of B-cell non-Hodgkin's lymphoma patients, with a total remission rate (ORR) of 57% in DLBCL patients and 93% in patients with class 1 to 3a FL.
in April this year, Reding Pharmaceuticals and Regeneration Yuan reached an agreement to obtain the exclusive commercial rights to the development and exclusive commercialization of cancer-related oncology in Chinese mainland, Hong Kong, Taiwan and Macau with a down payment of US$30 million and a registration and sales milestone payment of up to US$160 million.
this five were the first clinical approvals in China by REN1979.
a press release issued earlier by Reeding Pharmaceuticals, once REN1979 is approved for listing in China, Reding Pharmaceuticals will use its commercialization team to advance its commercialization efforts in the agreed area.
addition to this, the regeneratives will also receive some of the benefits of the future commercialization of REGEN1979.
, regeneratives will be responsible for the production and supply of REGEN1979 development and commercialization within the agreement area.
established in 2014, Redding Pharmaceuticals has deployed a wide range of product pipelines in the field of oncology and anti-infection, including more than 15 drug candidates, and more than 20 clinical trials are under way or planned.
Redding Pharmaceuticals currently has two products on the market: highly efficient and selective daily oral small molecule poly (ADP-UC) PARP1/2 inhibitor, Nel (Nirapali), which was approved for use in December 2019 to maintain treatment for adult patients with relapsed epitheliotic ovarian cancer, fallopian tube cancer or primary peripathic cancer with full or partial remission of platinum chemotherapy.
March 2020, CDE accepted Cyril's application for a new drug as a first-line maintenance treatment for ovarian cancer.
treats Epdon with an electric field, uses specific electric field frequencies to interfere with cell division, inhibit tumor growth, and kill cancer cells affected by electric field.
launched in Hong Kong in February 2019 for the treatment of glioblastoma (GBM) patients.
On May 13, 2020, Redding Pharmaceuticals and Novelcure announced that NMPA had approved Epdone's application for listing for the treatment of newly diagnosed glioblastoma patients in combination with terpenamine, as well as for patients with relapsed glioblastoma as a single therapy.
Epdon became the first Chinese mainland approved GBM therapy in 15 years.
2019 annual report, the company's 2019 revenue was $13 million, including $6.6 million in Hong Kong and Macau and $6.4 million in Hong Kong.
In addition, according to the IPO information, following the listing on NASDAQ on September 20, 2017, in recent days, Reding Pharmaceuticals will seek this week through the HKEx listing hearing, and within a few days on the HKEx official website to disclose the hearing after the prospect <2>, in order to complete the second listing on the HKEx as soon as September, no later than October.
that Reding Pharmaceuticals is expected to raise about $1bn, led by Citigroup, Goldman Sachs and JPMorgan Chase.
source: Medical Valley.com!-- content presentation ends -- !-- to determine whether the login ends.